As the breast cancer patients were on combined doxorubicin (or epirubicin) and cyclophosphamide therapy for 12 weeks followed by a further 12 weeks on paclitaxel (or docetaxel), we also investigated the effect of physiological levels of cyclophosphamide and paclitaxel on ABCA1. The gene discussed is ABCA1; the disease is breast carcinoma.